ライフサイエンスコーパス: Rous sarcoma virus

1 domain that is present in the Gag protein of Rous sarcoma virus.

2 dentified in the gag-specific protein p2b of Rous sarcoma virus.

3 homologue of v-src, the transforming gene of Rous Sarcoma virus.

4 ch controls fibroblast transformation by the Rous sarcoma virus.

5 ive regulator of splicing (NRS) element from Rous sarcoma virus.

6 nalyses of two in-vitro-assembled capsids of Rous sarcoma virus.

7 that of the naturally nonmyristoylated MA of Rous sarcoma virus.

8 1) and 2, simian immunodeficiency virus, and Rous sarcoma virus.

9 One mechanism by which Rous sarcoma virus achieves incomplete splicing involves

10 chicken embryo fibroblasts (CEF) infected by Rous sarcoma virus against a confluent background of uni

11 the cell dramatically reduced the release of Rous sarcoma virus, an avian retrovirus.

12 roviruses that undergo type C morphogenesis, Rous sarcoma virus and human immunodeficiency virus, whi

13 n the SU and TM envelope protein subunits of Rous sarcoma virus and murine leukemia virus.

14 s containing TATA and/or initiator elements, Rous sarcoma virus and thymidine kinase promoters in BeW

15 Tva is the receptor for subgroup A Rous sarcoma virus, and it contains a single LDL-A modul

16 peat (DR) sequences flanking the src gene in Rous sarcoma virus are essential posttranscriptional con

17 e experiments reported here, using the avian Rous sarcoma virus as a model system, further define the

18 erve as mRNA for the envelope protein and in Rous sarcoma virus as src mRNA.

19 polyprotein are intrinsic components of the Rous sarcoma virus assembly pathway.

20 We have constructed and characterized a Rous sarcoma virus-based retroviral vector with the host

21 that allowed for the first-time formation of Rous sarcoma virus CA into structures resembling authent

22 Instead, the Rous sarcoma virus capsid protein contains a single cyst

23 olecular disulfide bond during assembly, the Rous sarcoma virus capsid protein does not.

24 of charged amino acids on the surface of the Rous sarcoma virus capsid protein in the assembly of app

25 ed sequence similarity, the structure of the Rous sarcoma virus capsid protein is similar to the stru

26 ences that exist in the C-terminal domain of Rous sarcoma virus capsid relative to the other capsid p

27 on of baby hamster kidney fibroblasts by the Rous sarcoma virus causes a significant increase in the

28 totally unrelated late domain sequences from Rous sarcoma virus (contained in its p2b sequence) or eq

29 Using the Rous sarcoma virus-derived vector RCAS, we previously sh

30 Since codon composition values for Rous sarcoma virus distinguished a "foreign" gene from t

31 We have examined mutant Rous sarcoma virus envelope proteins with truncations or

32 unodeficiency virus type 1, visna virus, and Rous sarcoma virus exhibited different target site prefe

33 o- deficiency virus type 1, visna virus, and Rous sarcoma virus exhibited distinct preferences for wa

34 here that while deletion of the NC domain of Rous sarcoma virus Gag abolishes formation and budding o

35 Using purified Rous sarcoma virus Gag and Gag truncations, we studied t

36 icles (VLPs), we observed that expression of Rous sarcoma virus Gag failed to produce VLPs.

37 The Rous sarcoma virus gag gene contains a cis-acting negati

38 ture of the CA domains in immature assembled Rous sarcoma virus Gag particles.

39 In the context of the Rous sarcoma virus Gag polyprotein, only the nucleocapsi

40 It was shown previously that a Rous sarcoma virus Gag protein missing only the protease

41 The Rous sarcoma virus Gag protein undergoes transient nucle

42 purified, slightly truncated version of the Rous sarcoma virus Gag protein, Delta MBD Delta PR, and

43 rescence correlation spectroscopy-to examine Rous sarcoma virus Gag-Gag and -membrane interactions in

44 gion, Mpsi, from the 5' leader region of the Rous sarcoma virus genome that is sufficient to direct t

45 ckaging signal, MPsi, from the 5' end of the Rous sarcoma virus genome.

46 0 amino acid residue capsid protein from the Rous sarcoma virus has been determined by NMR methods.

47 structure of the three-domain integrase from Rous sarcoma virus in complex with viral and target DNAs

48 contrast, CEF cultures heavily infected with Rous sarcoma virus in the same medium underwent pervasiv

49 is tyrosine-phosphorylated when expressed in Rous sarcoma virus-infected chicken embryo fibroblasts (

50 plasmid acceptor, purified bacterium-derived Rous sarcoma virus integrase (IN), and a host cell DNA-b

51 ogous positions in visna virus integrase and Rous sarcoma virus integrase changed the target site pre

52 ous studies revealed that truncated forms of Rous sarcoma virus integrase containing two of the three

53 A direct comparison demonstrates that Rous sarcoma virus is capable of infecting aphidicolin-a

54 ct of the retroviral M domain from the avian Rous sarcoma virus is defined and its solution structure

55 Examination of the genomes of three Rous sarcoma virus isolates indicated that codon composi

56 quenced a small segment of the 3' end of the Rous sarcoma virus, just inside the poly(A) tail, at the

57 Although the integrity of the entire Rous sarcoma virus leader sequence is important for retr

58 binding chicken Y-box protein that promotes Rous sarcoma virus long terminal repeat (RSV LTR)-driven

59 ilar to the levels observed in vivo with the Rous sarcoma virus long terminal repeat constitutive pro

60 tained human factor IX (hFIX) cDNA driven by Rous sarcoma virus long terminal repeat in the E1 region

61 antibiotic-resistance gene was driven by the Rous sarcoma virus long terminal repeat or the herpes si

62 2(1) collagen promoters and 10-fold from the Rous sarcoma virus long terminal repeat.

63 ng MyoD under transcriptional control of the Rous sarcoma virus long terminal repeat.

64 of four promoters (dihydrofolate reductase, Rous sarcoma virus, long terminal repeat, or cytomegalov

65 1 is shown to transcriptionally activate the Rous sarcoma virus-long terminal repeat promoter, which

66 nducible, constitutively expressed reporter, Rous sarcoma virus-luciferase (RSV-LUC); nor does it blo

67 To further study the role of the Rous sarcoma virus MA sequence in the viral replication

68 us, all of the functions associated with the Rous sarcoma virus MA sequence must be contained within

69 o -90 confers FGF2/FSK responsiveness on the Rous sarcoma virus minimal promoter.

70 In vivo screening of Rous sarcoma virus mutants was performed with randomly m

71 the site phosphorylated by gamma-PAK in the Rous sarcoma virus nucleocapsid protein NC in vivo and i

72 ngeable late assembly domains carried by the Rous sarcoma virus p2b protein and human immunodeficienc

73 , human immunodeficiency virus type 1 p6, or Rous sarcoma virus p2b.

74 er of cis-acting sequences within the RNA of Rous sarcoma virus play a role in preserving a large poo

75 is virus integrase and bacterial recombinant Rous sarcoma virus (Prague A strain) integrase (approxim

76 Rous sarcoma virus pre-mRNA contains an element known as

77 In Rous sarcoma virus, previous studies have identified imp

78 coli lacZ reporter gene under control of the Rous sarcoma virus promoter and mammalian RNA processing

79 cloned into a pMAMneo vector containing the Rous sarcoma virus promoter and the neomycin resistance

80 r carrying the cDNA for C/EBPalpha driven by Rous sarcoma virus promoter elements (AdCEBPalpha) or a

81 which sig-mEndo expression was driven by the Rous sarcoma virus promoter had moderately high serum le

82 ls from the beta-galactosidase gene when the Rous sarcoma virus promoter is used to drive transgene e

83 riptional control of a constitutively active Rous sarcoma virus promoter was regulated identically to

84 endogenously expressing SDF-1/CXCL12 under a Rous sarcoma virus promoter were produced.

85 as an inducible HIV-1 genome controlled by a Rous sarcoma virus promoter with lac operator sequences.

86 porter beta-galactosidase gene driven by the Rous Sarcoma Virus promoter.

87 HIT, and CHO cells using cytomegalovirus or Rous sarcoma virus promoters.

88 The Rous sarcoma virus protease displays a high degree of sp

89 Other substrates such as the Rous sarcoma virus protein NC are phosphorylated by gamm

90 ervative substitutions in this region of the Rous sarcoma virus protein were lethal due to a severe d

91 f a weak src 3'ss is necessary for efficient Rous sarcoma virus replication.

92 resolution of a fragment of the integrase of Rous sarcoma virus (residues 49-286) containing both the

93 from human immunodeficiency virus type 1 or Rous sarcoma virus, respectively.

94 Cell transformation by Rous sarcoma virus results in a dramatic change of adhes

95 Rous sarcoma virus RNA contains a negative regulator of

96 Accumulation of unspliced Rous sarcoma virus RNA is facilitated in part by a negat

97 only 2.6-fold less efficiently than genomic Rous sarcoma virus RNA.

98 In particular, although both Rous sarcoma virus (RSV) and AMV could replicate in cult

99 ze budding of virus-like particles (VLPs) of Rous sarcoma virus (RSV) and HIV type 1 (HIV-1).

100 membrane binding, we fused the MA domains of Rous sarcoma virus (RSV) and HIV-1 to the chemically ind

101 the Gag protein; however, recent studies of Rous sarcoma virus (RSV) and human immunodeficiency viru

102 The Gag proteins of Rous sarcoma virus (RSV) and human immunodeficiency viru

103 The Gag proteins of Rous sarcoma virus (RSV) and human immunodeficiency viru

104 Rous sarcoma virus (RSV) and murine leukemia virus (MLV)

105 Rous sarcoma virus (RSV) and murine leukemia virus (MLV)

106 immunodeficiency virus type 1 (HIV-1) and of Rous sarcoma virus (RSV) are morphologically distinct wh

107 ssed this question using the alpharetrovirus Rous sarcoma virus (RSV) as a model system.

108 onducted to investigate the initial steps of Rous sarcoma virus (RSV) assembly by examining the assoc

109 Rous sarcoma virus (RSV) budding requires an interaction

110 The first few residues of the Rous sarcoma virus (RSV) CA protein comprise a structura

111 of charged residues in the FL region of the Rous sarcoma virus (RSV) CA to particle assembly.

112 d-state NMR (ssNMR) resonance assignments of Rous sarcoma virus (RSV) CA, assembled into hexamer tube

113 sembly incompetent by testing the ability of Rous sarcoma virus (RSV) CA-SP to assemble in vitro into

114 variety of specimens assembled in vitro from Rous sarcoma virus (RSV) CA.

115 The Gag protein of Rous sarcoma virus (RSV) can direct particle assembly an

116 structure of the N-terminal domain (NTD) of Rous sarcoma virus (RSV) capsid protein (CA), with an up

117 During virion maturation, the Rous sarcoma virus (RSV) capsid protein is cleaved from

118 an immunodeficiency virus type 1 (HIV-1) and Rous sarcoma virus (RSV) capsid proteins form a beta-hai

119 The cellular receptor for subgroup A Rous sarcoma virus (RSV) contains a single LDL-A module

120 ence appears to be modular, as the unrelated Rous sarcoma virus (RSV) Env can be made Vpu sensitive b

121 We have previously described a mutant Rous sarcoma virus (RSV) Env protein, Env-mu26, with an

122 this model, CA proteins from both HIV-1 and Rous sarcoma virus (RSV) form similar hexagonal lattices

123 We have identified an assembly-defective Rous sarcoma virus (RSV) Gag mutant that retains signifi

124 tudy in vitro-assembled, immature virus-like Rous sarcoma virus (RSV) Gag particles and have determin

125 triphosphate [PI(3,4,5)P(3)] levels impaired Rous sarcoma virus (RSV) Gag PM localization.

126 The p2 region of the Rous sarcoma virus (RSV) Gag polyprotein contains an ass

127 Nucleocytoplasmic shuttling of the Rous sarcoma virus (RSV) Gag polyprotein is an integral

128 The Rous sarcoma virus (RSV) Gag polyprotein undergoes trans

129 The Rous sarcoma virus (RSV) Gag precursor polyprotein is th

130 Proteolytic processing of the Rous sarcoma virus (RSV) Gag precursor was altered in vi

131 of the NC domain in assembly of VLPs from a Rous sarcoma virus (RSV) Gag protein and have characteri

132 We have purified Rous sarcoma virus (RSV) Gag protein and in parallel sev

133 The first 86 residues of the Rous sarcoma virus (RSV) Gag protein form a membrane-bin

134 ously reported that nuclear transport of the Rous sarcoma virus (RSV) Gag protein is intrinsic to the

135 med spontaneously in vitro from fragments of Rous sarcoma virus (RSV) Gag protein purified after expr

136 ped three very small, modular regions of the Rous sarcoma virus (RSV) Gag protein that are necessary

137 We discovered that the Rous sarcoma virus (RSV) Gag protein transiently localiz

138 In the Rous sarcoma virus (RSV) Gag protein, the 25 amino-acid

139 In the Rous sarcoma virus (RSV) Gag protein, the M domain is co

140 een these two hypotheses, we made use of the Rous sarcoma virus (RSV) Gag protein, the PR of RSV IS i

141 erminal 100 residues of the non-myristylated Rous sarcoma virus (RSV) Gag protein.

142 We used Rous sarcoma virus (RSV) Gag together with membrane sens

143 eption was the 11-amino-acid p2b sequence of Rous sarcoma virus (RSV) Gag, which could fully restore

144 essential steps in understanding the chicken Rous sarcoma virus (RSV) genome association with a nonpe

145 elatively short, 82 nucleotide region of the Rous sarcoma virus (RSV) genome, called muPsi, was shown

146 The major late domain of Rous sarcoma virus (RSV) has been mapped to a PPPY motif

147 The L domain of Rous sarcoma virus (RSV) has been shown to interact with

148 t, the L domains of oncoretroviruses such as Rous sarcoma virus (RSV) have a more N-terminal location

149 We produced kinetically stabilized Rous sarcoma virus (RSV) intasomes with human immunodefi

150 Site-directed mutagenesis of recombinant Rous sarcoma virus (RSV) integrase (IN) allowed us to ga

151 nhanced when the serine at amino acid 124 of Rous sarcoma virus (RSV) integrase is replaced by alanin

152 The Rous sarcoma virus (RSV) is an exception, in that its ge

153 About one-third of the MA protein in Rous sarcoma virus (RSV) is phosphorylated.

154 we have examined whether the alpharetrovirus Rous sarcoma virus (RSV) is susceptible to inhibition by

155 proteins that specifically interact with the Rous sarcoma virus (RSV) L domain in vitro and in vivo.

156 The discovery of Rous sarcoma virus (RSV) led to the identification of ce

157 taining the ts gene under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) and

158 dogenous AAV promoters, p5 and p40, with the Rous sarcoma virus (RSV) long terminal repeat (LTR) and

159 eracts with the Schmidt-Ruppin strain of the Rous sarcoma virus (RSV) long terminal repeat (LTR) betw

160 The Rous sarcoma virus (RSV) long terminal repeat (LTR) cont

161 The Rous sarcoma virus (RSV) long terminal repeat (LTR) cont

162 CC-3' present on the noncoding strand of the Rous sarcoma virus (RSV) long terminal repeat (LTR) in a

163 eceptor (ecoR) cDNA under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) prom

164 alovirus (CMV) immediate-early promoter, the Rous sarcoma virus (RSV) long terminal repeat, and the a

165 ts within the avian leukosis virus (ALV) and Rous sarcoma virus (RSV) LTR enhancers in a pattern iden

166 ssociation of HIV-1 Gag, as well as purified Rous sarcoma virus (RSV) MA and Gag, depends strongly on

167 in vitro flotation assay to directly measure Rous sarcoma virus (RSV) MA-membrane interaction in the

168 rted repeat (IR) within the U5 region of the Rous sarcoma virus (RSV) mRNA forms a structure composed

169 In this report, a Rous sarcoma virus (RSV) mutant having two acidic-to-bas

170 The Rous sarcoma virus (RSV) negative regulator of splicing

171 135-nucleotide (nt) direct repeats flank the Rous sarcoma virus (RSV) oncogene src and are composed o

172 virus-based vector LNCX, contain an internal Rous sarcoma virus (RSV) or cytomegalovirus (CMV) promot

173 ctivity compared with strong but nonspecific rous sarcoma virus (RSV) or cytomegalovirus promoters.

174 The late assembly domain (L-domain) of Rous sarcoma virus (RSV) or human immunodeficiency virus

175 virus (EIAV) is functionally homologous with Rous sarcoma virus (RSV) p2b and human immunodeficiency

176 ent of Gag in in vivo and in vitro assembled Rous sarcoma virus (RSV) particles and to compare these

177 However, in the presence of budding HIV-1 or Rous sarcoma virus (RSV) particles, some glycoproteins,

178 The Rous sarcoma virus (RSV) polyadenylation site (PAS) is v

179 mmunodeficiency virus type 1 (HIV-1) PTAP or Rous sarcoma virus (RSV) PPPY L domain in the p9 protein

180 t the enzymatic and structural properties of Rous sarcoma virus (RSV) PR are exquisitely sensitive to

181 pHyde gene under the control of a truncated Rous sarcoma virus (RSV) promoter (AdRSVpHyde) was gener

182 he cDNA for human iNOS was cloned behind the Rous sarcoma virus (RSV) promoter to create adenovirus (

183 Rous sarcoma virus (RSV) promoter-driven expression of t

184 novirus containing the HERG gene driven by a Rous sarcoma virus (RSV) promoter.

185 ontrol of the human cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoters.

186 enzyme, resulting in a highly active mutant Rous sarcoma virus (RSV) protease that displays many cha

187 ld be initiated by electroporation of cloned Rous sarcoma virus (RSV) proviral DNA into the developin

188 Expression of the Gag-Pol polyprotein of Rous sarcoma virus (RSV) requires a -1 ribosomal framesh

189 Rous sarcoma virus (RSV) requires large amounts of unspl

190 We asked whether a single Rous sarcoma virus (RSV) RNA can be translated and subse

191 The 5' untranslated region of Rous sarcoma virus (RSV) RNA is a highly ordered structu

192 inding site in the 5' untranslated region of Rous sarcoma virus (RSV) RNA play an integral role in mu

193 ing element in the 3' untranslated region of Rous sarcoma virus (RSV) RNA was found to promote Rev-in

194 We previously identified the Rous sarcoma virus (RSV) stability element (RSE), an RNA

195 a mouse monoclonal antibody directed against Rous sarcoma virus (RSV) subgroup A Env that will be use

196 produce milligram quantities of the soluble Rous sarcoma virus (RSV) synaptic complex that is kineti

197 describes new mutations in the CA protein of Rous sarcoma virus (RSV) that were designed to test whet

198 In chick embryo fibroblasts transformed by Rous sarcoma virus (RSV) the tyrosine phosphorylation of

199 V), feline immunodeficiency virus (FIV), and Rous sarcoma virus (RSV) to critically address the role

200 The Rous sarcoma virus (RSV) transmembrane (TM) glycoprotein

201 ne transport, the multidomain Gag protein of Rous sarcoma virus (RSV) undergoes importin-mediated nuc

202 RNA(Lys3) as the replication primer, whereas Rous sarcoma virus (RSV) uses tRNA(Trp).

203 discovery from Ray Erikson's group that the Rous sarcoma virus (RSV) v-Src-transforming protein had

204 ol vector containing a constitutively active Rous sarcoma virus (RSV) viral promoter driving the luci

205 A PPPPY motif within the L domain of Rous sarcoma virus (RSV) was previously characterized as

206 y reactions with purified CA proteins of the Rous sarcoma virus (RSV) were used to define factors tha

207 We previously reported that a mutant Rous sarcoma virus (RSV) with an alternate polypurine tr

208 Rous sarcoma virus (RSV), a simple retrovirus, needs to

209 resembles the PPPPY motif in the L domain of Rous sarcoma virus (RSV), an avian retrovirus.

210 HIV-1, Moloney murine leukemia virus (MLV), Rous sarcoma virus (RSV), and human T-cell lymphotropic

211 human immunodeficiency virus type 1 (HIV-1), Rous sarcoma virus (RSV), and Mason-Pfizer monkey virus

212 articles of the prototypic avian retrovirus, Rous sarcoma virus (RSV), by using scanning transmission

213 In some orthoretroviruses, including Rous Sarcoma Virus (RSV), CA carries a short and hydroph

214 ton Rous recovered a virus, now known as the Rous sarcoma virus (RSV), from a chicken sarcoma, which

215 For Rous sarcoma virus (RSV), Gag proteins are synthesized i

216 osed based on the existence of MA mutants in Rous sarcoma virus (RSV), murine leukemia virus, human i

217 During assembly and morphogenesis of Rous sarcoma virus (RSV), proteolytic processing of the

218 For Rous sarcoma virus (RSV), the size determinant maps to t

219 In the case of Rous sarcoma virus (RSV), the size determinant maps to t

220 , a Gammaretrovirus, and the Alpharetrovirus Rous sarcoma virus (RSV), were susceptible to inhibition

221 eplication-competent shuttle vector based on Rous sarcoma virus (RSV), with alternate retroviral PPTs

222 the utility of the system, we developed new Rous sarcoma virus (RSV)-based replication-incompetent v

223 tween the PBS and the CA dinucleotide of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z to matc

224 the endogenous polypurine tract (PPT) of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z was rep

225 ions in the 5' end of the U3 sequence of the Rous sarcoma virus (RSV)-derived vector RSVP(A)Z.

226 stablishment of the transformed phenotype in Rous sarcoma virus (RSV)-infected cells.

227 eplication-defective adenoviral vectors [Adv.Rous sarcoma virus (RSV)-nf] representing three families

228 vector encoding a peptide inhibitor of PKA [Rous sarcoma virus (RSV)-protein kinase A inhibitor (PKI

229 Rous sarcoma virus (RSV)-tk bearing the HSV1-tk gene wer

230 the robustly induced enzymatic activities in Rous sarcoma virus (RSV)-transformed chicken cells.

231 tures found in osteoclasts, macrophages, and Rous sarcoma virus (RSV)-transformed fibroblasts.

232 ng a well-established retroviral model-avian Rous sarcoma virus (RSV)-we analyzed changes in an RSV v

233 icken embryo fibroblasts (CEF) infected with Rous sarcoma virus (RSV).

234 odel retroviral envelope protein (EnvA) from Rous sarcoma virus (RSV).

235 +)-ATPase (SERCA2a) under the control of the Rous sarcoma virus (RSV).

236 ric interactions between the Gag proteins of Rous sarcoma virus (RSV).

237 ansforming viral oncogene product encoded by Rous sarcoma virus (RSV).

238 d CRM1-dependent nuclear cycling was that of Rous sarcoma virus (RSV).

239 -membrane interaction of the alpharetrovirus Rous sarcoma virus (RSV).

240 ecades of study on an avian RNA tumor virus, Rous sarcoma virus (RSV).

241 In Rous sarcoma virus, splicing control is achieved in part

242 downstream from the 3'ss of the heterologous Rous sarcoma virus src gene.

243 e 3' splice site in the BPV-1 late pre-mRNA, Rous sarcoma virus src pre-mRNA, human immunodeficiency

244 As also found for other retroviruses, the Rous sarcoma virus structural protein Gag is necessary a

245 he negative regulator of splicing (NRS) from Rous sarcoma virus suppresses viral RNA splicing and is

246 ng (NRS) is a long cis-acting RNA element in Rous sarcoma virus that contributes to unspliced RNA acc

247 a mutant of the viral matrix (MA) protein of Rous sarcoma virus that disrupts viral RNA dimerization.

248 gate Gag protein structure and processing in Rous sarcoma virus, the prototype of the avian sarcoma a

249 e used cryo-electron tomography to visualize Rous sarcoma virus, the prototypic alpharetrovirus.

250 e-bound nonreceptor tyrosine kinase Src from Rous sarcoma virus, these interactions are mediated by a

251 In HIV-1 and Rous sarcoma virus, this region forms a rod-like structu

252 to as antisense, can inhibit replication of Rous sarcoma virus through hybridization to viral RNA.

253 initially identified as a phosphoprotein in Rous sarcoma virus-transformed cells.

254 iruses containing the cellular receptors for Rous sarcoma virus (Tva) or ecotropic murine leukemia vi

255 We find that Rous sarcoma virus virions, like the human immunodeficie

256 by his discovery of reverse transcriptase in Rous sarcoma virus virions.

257 By cryoelectron tomography, Rous sarcoma virus VLPs show an organized hexameric latt

258 natural or mutated 5' leader sequences from Rous sarcoma virus were expressed in avian cells in the

259 ses, including the prototypic oncoretrovirus Rous sarcoma virus, were synthesized on cytosolic riboso

260 The discovery of Rous sarcoma virus, which was reported by Peyton Rous in

261 HT29, and CaCo2) compared with a nonspecific Rous sarcoma virus-yCD virus.